Agendia will use Rubicon Genomics' whole-genome RNA amplification technology in its breast cancer diagnostic tests, Rubicon said today.
Under a clinical supply agreement, Agendia will apply Rubicon's TransPlex technology to analyze formalin-fixed, paraffin-embedded patient samples on Agendia's Symphony suite of breast cancer diagnostics.
RNA or DNA extracted from FFPE samples is highly fragmented and often contains only small amounts of usable DNA or RNA, which may be insufficient for analysis. Rubicon's TransPlex and GenomePlex amplification kits are members of Rubicon's OmniPlex family of technologies, and have been shown to be able to overcome these problems and deliver sufficient quantities of high-quality nucleic acids to enable accurate and consistent analyses, the company said.
In a statement, Rubicon CEO James Koziarz called the deal an important milestone for his firm. "This supply agreement with cancer diagnostics pioneer Agendia represents our first large-scale commercial partnership with a provider of clinical diagnostic tests, and we expect it to be the first of many going forward," he said.
Financial and other terms of the deal were not disclosed.